Hipposponols A and B, two new 9, 11-secosterols from the marine sponge de Laubenfels.

Two new 9,11-secosterols, hipposponols A () and B (), together with five known analogues, aplidiasterol B (), (3,5,6)-3,5,6-triol-cholest-7-ene (), (3,5,6,22)-3,5,6-triol-ergosta-7,22-diene (), and one pair of inseparable C-24 epimers of (3,5,6,22E)-3,5,6-triol-stigmasta-7,22-diene (/), were isolated from the marine sponge de Laubenfels. The structures of isolated compounds were extensively elucidated based on HRESIMS and NMR data. Compounds - showed cytotoxicity against PC9 cells with IC values ranging from 34.

[The improvement effect of scFv17 on the gait of triple-transgenic mice].

Objective: To observe the gait changes of Alzheimer's disease PS1M146V/APPswe/tauP301L triple-transgenic (3xTg-AD) mice and to investigate the improvement effect of single chain variable domain antibody fragment 17 (scFv17) on the gait.

Methods: In the present study, a selection of 6-month-old 3xTg-AD mice (=18) and C57BL/6 wild-type mice (=24) was performed. First, we observed their gait changes and found that the gait of 12-month-old 3xTg-AD mice was severely damaged.

[Expressions of synaptophysin and BDNF/Trk-B in cerebellum of APPswe/PS1dE9 transgenic mice].

Objective: To observe the expressions of synaptophysin and BDNF/Trk-B in cerebellum of APPswe/PS1dE9 transgenic mice.

Methods: The healthy 9-month old APP/PS1 male mice (n1) and the same wild type male mice(n2) were divided into two groups, APP/PS1 group and wild-type(WT) group. The expressions of synaptophysin and brain-derived neurotrophic factor/tyrosine kinase B (BDNF/Trk-B) in cerebellum were determined by Western blot (n1=6; n2=6) and immunohistochemical(n1=4; n2=4).

[Effects of adiponectin on the anxiety and memory impairment in triple transgenic Alzheimer's disease model mice].

Objective: To investigate the effects of adiponectin (APN) on anxiety and memory impairment of 9-month-old triple transgenic Alzheimer's disease (3xTg-AD) model mice.

Methods: The 9-month-old 3xTg-AD mice and C57BL/6J mice were randomly divided into four groups (=8 for each group):Wild type(WT)+Saline, 3xTg-AD +Saline, WT+APN and 3xTg-AD +APN group. All mice were implanted cannula in lateral ventricle and each mouse was intracerebroventricular injected with adiponectin or saline under free moving condition after 7 days recovery.

A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease.

Type 2 diabetes mellitus (T2DM) is an important risk factor for Alzheimer's disease (AD). Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have been identified to be effective in T2DM treatment and neuroprotection. In this study, we further explored the effects of a novel unimolecular GLP-1/GIP/Gcg triagonist on the cognitive behavior and cerebral pathology in the 7-month-old triple transgenic mouse model of AD (3xTg-AD), and investigated its possible electrophysiological and molecular mechanisms.

[GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease].

Alzheimer's disease (AD) is a progressively neurodegenerative disorder, which seriously affects human health but is still irreversible up to now. Recent studies indicate that type 2 diabetes mellitus (T2DM) is an important risk factor for AD, and the drugs used for treatment of T2DM have shown some neuroprotective effects in the treatment of AD. Glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP)/glucagon (Gcg) receptor Triagonist is a new monomeric polypeptide equally activating the GLP-1/GIP/Gcg receptors, which is built on the basis of GLP-1/Gcg receptor coagonist core sequence, and incorporated with partial amino acids of GIP.